Skip to main content
Figure 4 | Arthritis Research & Therapy

Figure 4

From: Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation

Figure 4

Relapse after treatment discontinuation is independent of the presence of antiadalimumab antidrug antibodies. Antiadalimumab antidrug antibodies (ADAbs) at the end of treatment, 2 weeks after the last injection, were not different between patients who did vs. those who did not relapse after discontinuation of adalimumab (A). There was no difference in time to relapse in patients who tested positive vs. those who tested negative for antiadalimumab ADAbs (B) Median (interquartile range).

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us